Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 6, 1998, Pages 605-607

  Sadoff, Leonard ^a,b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

5 Fluorouracil toxicity; Diabetes mellitus; Hyperglycemia; Tumor glycolysis

Indexed keywords

CISPLATIN; FLUOROURACIL;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DIABETES MELLITUS; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG FATALITY; DRUG INDUCED DISEASE; HUMAN; HYPERGLYCEMIA; MALE; MOUTH CANCER; STOMATITIS;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIABETES COMPLICATIONS; FEMALE; FLUOROURACIL; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0031765675     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199812000-00015     Document Type: Article

References (21)

1. Wodinsky H, Lion J, De Angelis C, et al. Chemotherapy in Canada utilization and costs in Ontario's freestanding cancer centers, part 1. Cancer Management 1996;12:14-20.
2. Senn HJ, Maibach M, Jungi WF, et al. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide methotrexate and fluorouracil - 11 year results of Swiss group for clinical cancer research trial SAKK 27/82. J Clin Oncol 1997;15:2502-9.
3. Zamboni A. Adjuvant chemotherapy in colo-rectal carcinoma with high dose leucovorin and fluorouracil: impact on disease free survival and overall survival. J Clin Oncol 1997;15:2432-41.
4. Al-Sarraf M, Martz K, Herskovic L, et al. Progress report of combined chemoradiotherapy vs radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84.
5. Clark JR, Busse PM, Norris CM, et al. Induction chemotherapy with cisplatin, fluorouracil and high dose leucovorin for squamous cell carcinoma of the head and neck: long term results. J Clin Oncol 1997;15:3100-10.
6. Steinherz LJ, Yahalom J. Toxicity. In: Devita DV Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997;2745-6.
7. Vokes EE, Ratain MJ, Mick RM, et al. Cisplatin, fluorouracil and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 1993;11:360-8.
8. Milano G, Etienne MC, Thyss A, et al. Influence of age and sex on fluorouracil clearance. J Clin Oncol 1992;10:1171-5.
9. Sobero AF, Aschele C, Bertino JR. Fluorouracil in colo-rectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-81.
10. Floyd RA, Hornbeek CL, Byfield JE, et al. Clearance of continuously infused 5FU in adults having lung or gastrointestinal cancer with or without hepatic metastases. Drug Intelligence and Clinical Pharmacy 1982;16:665-7.
11. Kish JA, Weaver A, Jacobs J, et al. Cisplat and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984;53:1819-24.
12. Tiedbois P, Buyse M, Blijham G, et al. Advanced colo-rectal cancer metaanalysis project: meta analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colo-rectal cancer. J Clin Oncol 1994;12:960-9.
13. Poon MA, Oconnell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colo-rectal carcinoma. J Clin Oncol 1989;7:1407-8.
14. Raderer M, Scheifhauer W. Treatment of advanced colo-rectal cancer with fluorouracil and interferon alpha: an overview of clinical trials. Eur J Cancer 1995;31:1002-8.
15. Petit E, Milano G, Levi R, et al. Circadian rhythm-varying plasma contraction of 5-fluorouracil during a five day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988;48:1676-9.
16. Harris BE, Song R, Song SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma levels in cancer patients receiving 5-fluorouracil by protracted infusion. Cancer Res 1990;50:197-201.
17. Tuchman M, Stoeckeler JS, Kiang DT, et al. Familial pyrimidinemia and pyriminuria associated with severe 5-fluorouracil toxicity. New Engl J Med 1985;245-9.
18. Woods MW, Burks D. Antiglycolytic activities of 5-FU and related pyrimidines in mouse ascites carcinoma cells with special reference to inorganic phosphate and glucose. Oncology 1969;12:1-32.
19. Kung SS, Goldberg ND, Dahl JL, et al. Potentiation of 5-FU inhibition of Flexner-Jobling carcinoma by glucose. Science 1963;141:627-8.
20. Som P, Atkins HL. Bandoypadhyah D, et al. A fluorinated glucose analog, 2-fluoro-deoxy-D-glucose (f-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980;21:670-5.
21. Gabbay KH. Hyperglycemia, polyol metabolism and complications of diabetes. Annu Rev Med 1975;26:521-6.